Skip to content
DataLookout
Menu

CLINCH-3NCT07795346

A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Trial sites expanded: 114 → 131 locations
    • Start date changed from estimate of Sep 1, 2026 to Sep 17, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Progression-Free Survival(PFS )
Timeframe: From randomization to first PD or death. Tumour assessments at baseline, q6w (±1w) during treatment, q12w (±1w) after 12m, q24w (±1w) after 24m, until PD/death/study end (~228 OS events, ~1yr after LPI).
Overall Survival(OS)
Timeframe: From randomization to death. Survival follow-up q3m (±14d) until death/study termination (~228 OS events).

Secondary (3)

Objective response rate (ORR)
Disease control rate (DCR)
Duration of response (DOR)

Arms and interventions

ATG-022Experimental
Docetaxel or IrinotecanActive comparator

Drugs: ATG-022, Docetaxel or Irinotecan

Sites

131 sites in 1 country